Molecular Partners AG (NASDAQ:MOLN - Get Free Report) shares shot up 2.9% on Tuesday . The company traded as high as $4.03 and last traded at $3.88. 4,417 shares traded hands during trading, a decline of 77% from the average session volume of 19,383 shares. The stock had previously closed at $3.77.
Wall Street Analysts Forecast Growth
Separately, Lifesci Capital assumed coverage on shares of Molecular Partners in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $12.00 price objective for the company.
View Our Latest Stock Report on Molecular Partners
Molecular Partners Stock Up 2.9 %
The company has a market capitalization of $156.66 million, a price-to-earnings ratio of -1.80 and a beta of 1.16. The business has a fifty day simple moving average of $4.27 and a two-hundred day simple moving average of $5.02.
Molecular Partners (NASDAQ:MOLN - Get Free Report) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.11. Molecular Partners had a negative return on equity of 39.31% and a negative net margin of 1,043.01%. As a group, equities analysts predict that Molecular Partners AG will post -1.93 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Molecular Partners
A hedge fund recently raised its stake in Molecular Partners stock. BVF Inc. IL raised its position in shares of Molecular Partners AG (NASDAQ:MOLN - Free Report) by 205.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,353,968 shares of the company's stock after buying an additional 910,747 shares during the period. BVF Inc. IL owned about 3.35% of Molecular Partners worth $6,458,000 as of its most recent filing with the Securities and Exchange Commission. 26.55% of the stock is currently owned by hedge funds and other institutional investors.
About Molecular Partners
(
Get Free Report)
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Molecular Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Molecular Partners wasn't on the list.
While Molecular Partners currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
